JP2022517517A5 - - Google Patents

Info

Publication number
JP2022517517A5
JP2022517517A5 JP2021534294A JP2021534294A JP2022517517A5 JP 2022517517 A5 JP2022517517 A5 JP 2022517517A5 JP 2021534294 A JP2021534294 A JP 2021534294A JP 2021534294 A JP2021534294 A JP 2021534294A JP 2022517517 A5 JP2022517517 A5 JP 2022517517A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glioma
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517517A (ja
JP7746157B2 (ja
Filing date
Publication date
Priority claimed from EP18382917.5A external-priority patent/EP3666266A1/en
Application filed filed Critical
Publication of JP2022517517A publication Critical patent/JP2022517517A/ja
Publication of JP2022517517A5 publication Critical patent/JP2022517517A5/ja
Application granted granted Critical
Publication of JP7746157B2 publication Critical patent/JP7746157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534294A 2018-12-12 2019-12-12 膠芽腫の治療および予防 Active JP7746157B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382917.5A EP3666266A1 (en) 2018-12-12 2018-12-12 Treatment and prevention of glioblastoma
EP18382917.5 2018-12-12
PCT/EP2019/084822 WO2020120656A1 (en) 2018-12-12 2019-12-12 Treatment and prevention of glioblastoma

Publications (3)

Publication Number Publication Date
JP2022517517A JP2022517517A (ja) 2022-03-09
JP2022517517A5 true JP2022517517A5 (https=) 2022-12-20
JP7746157B2 JP7746157B2 (ja) 2025-09-30

Family

ID=64746483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534294A Active JP7746157B2 (ja) 2018-12-12 2019-12-12 膠芽腫の治療および予防

Country Status (7)

Country Link
US (1) US20220008362A1 (https=)
EP (2) EP3666266A1 (https=)
JP (1) JP7746157B2 (https=)
CN (1) CN113365619A (https=)
CA (1) CA3122640A1 (https=)
ES (1) ES2986469T3 (https=)
WO (1) WO2020120656A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3048032A1 (es) * 2025-05-27 2025-12-05 Univ Madrid Complutense N-(4-Ariloxi-3-hidroxibutan-2-il)alcanamidas con actividad antagonista adrenérgica beta-2 selectiva

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121500A1 (en) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of ventilator-induced diaphragmatic dysfunction

Similar Documents

Publication Publication Date Title
JP2017518334A5 (https=)
JP2014500861A5 (https=)
JP2019031560A5 (https=)
JP2008512490A5 (https=)
JP2016520618A5 (https=)
JP2009536620A5 (https=)
JP2018518537A5 (https=)
JP2006503850A5 (https=)
JP2016534063A5 (https=)
JP2013542261A5 (https=)
JP2012513416A5 (https=)
JP2013507415A5 (https=)
JP2011500545A5 (https=)
JP2011526924A5 (https=)
JP2008501705A5 (https=)
JP2009531376A5 (https=)
CN105120868A (zh) 组合治疗
JP2018529742A5 (https=)
JP2010527984A5 (https=)
JP2011524896A5 (https=)
JP2008534453A5 (https=)
WO2019106604A1 (en) Pharmaceutical combination comprising lsz102 and alpelisib
JP2007505044A5 (https=)
JP2021534160A5 (https=)
JP2022517517A5 (https=)